The Base Prospectus dated 12 July 2022 expires on 11 July 2023. The updated Base Prospectus shall be available for viewing free of charge on the website of the AMF and on www.amundi.com

PROHIBITION OF SALES TO UK RETAIL INVESTORS – The Securities are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the United Kingdom (UK). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client, as defined in point (8) of Article 2 of Commission Delegated Regulation (EU) No 2017/565 (as amended) as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (EUWA); (ii) a customer within the meaning of the provisions of the FSMA and any rules or regulations made under the FSMA to implement Directive (EU) 2016/97 (as amended), where that customer would not qualify as a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 (as amended) as it forms part of domestic law by virtue of the EUWA; or (iii) not a qualified investor as defined in Article 2 of Regulation (EU) 2017/1129 (as amended) as it forms part of domestic law by virtue of the EUWA. Consequently no key information document required by Regulation (EU) No 1286/2014 (as amended) as it forms part of domestic law by virtue of the EUWA (the UK PRIIPs Regulation) for offering or selling the Securities or otherwise making them available to retail investors in the UK has been prepared and therefore offering or selling the Securities or otherwise making them available to any retail investor in the UK may be unlawful under the UK PRIIPs Regulation.

MiFID II Product Governance / Retail investors, professional investors and eligible counterparties target market – Solely for the purposes of the manufacturer's product approval process, the target market assessment in respect of the Securities, taking into account the five categories referred to in item 18 of the Guidelines published by ESMA has led to the conclusion that: (i) the target market for the Securities is eligible counterparties, professional clients and retail clients, each as defined in MiFID II; and (ii) all channels for distribution to eligible counterparties and professional clients are appropriate; and (iii) the following channels for distribution of the Securities to retail clients are appropriate - investment advice and portfolio management, and pure execution services, subject to the distributor's suitability and appropriateness obligations under MiFID II, as applicable.

Any person subsequently offering, selling or recommending the Securities (a distributor) should take into consideration the manufacturer's target market assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the Securities (by either adopting or refining the manufacturer's target market assessment) and determining appropriate distribution channels, subject to the distributor's suitability and appropriateness obligations under MiFID II, as applicable.

**UK MIFIR product governance / Retail investors, professional investors and eligible counterparties target market** – Solely for the purposes of the manufacturer's product approval process, the target market assessment in respect of the Securities, taking into account the five categories referred to in item 18 of the Guidelines published by the ESMA on 5 February 2018 (in accordance with the FCA's policy statement entitled "Brexit our approach to EU non-legislative materials"), has led to the conclusion that: (i) the target market for the Securities is retail clients, as defined in point (8) of Article 2 of Commission Delegated Regulation (EU) No 2017/565 (as amended) as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (**EUWA**), and eligible counterparties, as defined in the FCA Handbook Conduct of Business Sourcebook (**COBS**) and professional clients, as defined in Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA (**UK MiFIR**); and (ii) all channels for distribution to eligible counterparties and professional clients are appropriate; and (iii) the following channels for distribution of the Securities to retail clients are appropriate investment advice and portfolio management, and pure execution services, subject to the distributor's suitability and appropriateness obligations under COBS, as applicable.

Any person subsequently offering, selling or recommending the Securities (a **distributor**) should take into consideration the manufacturer's target market assessment; however, a distributor subject to the FCA Handbook Product Intervention and Product Governance Sourcebook (the **UK MiFIR Product Governance Rules**) is responsible for undertaking its own target market assessment in respect of the Securities (by either adopting or refining the manufacturer's target market assessment) and determining appropriate distribution channels, subject to the distributor's suitability and appropriateness obligations under COBS, as applicable.

#### FINAL TERMS DATED 27 JUNE 2023

#### Amundi

# Legal Entity Identifier (LEI): 96950010FL2T1TJKR531

Issue of 30 000 000 € of Notes Obligation Equilibre Spirica (Juillet 2023) by Amundi

under the Euro 10,000,000,000 Notes and Certificates Programme

The Base Prospectus referred to below (as supplemented by these Final Terms) has been prepared on the assumption that, other than as provided in sub-paragraph (ii) below, any offering of Certificates in any member state of the European Economic Area (each a **Member State**) shall be made pursuant to an exemption from the requirement to publish a prospectus for offers of Certificates, in accordance with the Prospectus Regulation. Accordingly, any person offering or intending to offer Certificates may only do so:

- (i) in circumstances under which neither the Issuer nor any Dealer is under any obligation to publish a prospectus pursuant to article 3 of the Prospectus Regulation or a supplemental prospectus in accordance with article 23 of the Prospectus Regulation; or
- (ii) in a Non-Exempt Offer Jurisdiction as referred to in paragraph 33 of Part A below, provided that such person is one of the persons referred to in paragraph 33 of Part A below and that such offer is made during the Offer Period specified for such purpose in such same paragraph.

Neither the Issuer nor any Dealer has authorised or authorises the offering of any Certificates in any other circumstances.

The expression **Prospectus Regulation** means the Regulation (EU) 2017/1129 of the European Parliament and the Council dated 14 June 2017 as amended.

### PART A - CONTRACTUAL TERMS

Terms used herein shall be deemed to be defined as such for the purposes of the Conditions (the **Conditions**) set forth in the Base Prospectus dated 12 July 2022, the first supplement to the Base Prospectus dated 17 August 2022, the second supplement to the Base Prospectus dated 23 September 2022, the third supplement to the Base Prospectus dated 14 November 2022, the fourth supplement to the Base Prospectus dated 17 February 2023 and the fifth supplement to the Base Prospectus dated 16 May 2023, published and approved on or before the date of these Final Terms (copies of which are available as described below) notwithstanding the publication and approval of any other Supplement to the 2022 Base Prospectus (each a **2022 Future Supplement**) which may have been published and approved (together, the **2022 Base Prospectus**) after the date of these Final Terms and before the issue of the Certificates to which these Final Terms relate and an updated Base Prospectus (any Supplement(s) thereto, each a **2023 Future Supplement**), which will replace the 2022 Base Prospectus (the **2023 Base Prospectus**) (the date of any such publication and approval, each a **Publication Date**). This document constitutes

the Final Terms of the Certificates described herein for the purposes of the Prospectus Regulation and (i) prior to any Publication Date, must be read in conjunction with the 2022 Base Prospectus, or (ii) on and after any Publication Date must be read in conjunction with the 2022 Base Prospectus, as supplemented by any 2022 Future Supplement as at such date or, as applicable, the 2023 Base Prospectus, as supplemented by any 2023 Future Supplement as at such date, save in respect of the Conditions which are extracted from the 2022 Base Prospectus. The 2022 Base Prospectus, as supplemented, constitutes, and the 2023 Base Prospectus will constitute, a base prospectus for the purposes of the Prospectus Regulation. Full information on Amundi (the Issuer) and the offer of the Certificates is only available on the basis of the combination of these Final Terms and (i) prior to any Publication Date, the 2022 Base Prospectus, or (ii) on or after any Publication Date, the 2022 Base Prospectus, as supplemented by any 2022 Future Supplement as at such date or, as applicable, the 2023 Base Prospectus, as supplemented by any 2023 Future Supplement as at such date, save in respect of the Conditions which are extracted from the 2022 Base Prospectus. The Issuer has in the 2022 Base Prospectus given consent to the use of the 2022 Base Prospectus in connection with the offer of the Certificates. Such consent will be valid until the date that is twelve months following the date of the 2022 Base Prospectus. The Issuer will in the 2023 Base Prospectus give consent to the use of the 2023 Base Prospectus in connection with the offer of the Certificates. The 2022 Base Prospectus, as supplemented, and these Final Terms are available, and the 2023 Base Prospectus will be available on website of the Issuer (https://about.amundi.com ). The 2022 Base Prospectus, and these Final Terms and the Supplements to the 2022 Base Prospectus will also be available on the AMF website www.amf-france.org

A summary of the issue is appended to these Final Terms and includes the information contained in the summary of the 2022 Base Prospectus and relevant information on the Final Terms.

1.	(i)	Issuer:	Amundi
2.	(i)	Series N°:	37
	(ii)	Tranche N°:	1
	(iii)	Date on which the Notes become fungible:	Not Applicable
3.	Specified Currency(ies):		Euro ("€")
	Replacement Currency		U.S. dollar
4.	Aggregate Nominal Amount:		30 000 000 €
5.	Issue Price:		100 per cent. of the Aggregate Nominal Amount
6.	(i)	Specified Dénomination	100 €
	(ii)	Calculation Amount:	Specified Denomination
7.	(i)	Issue Date:	29 june 2023
	(ii)	Trade Date:	20 june 2023
	(iii)	Interest Period Commencement Date:	Not Applicable
8.	Maturity Date:		28 july 2033

9. Interest Basis: Zero Coupon

10. Coupon Switch Option: Not Applicable

11. Redemption/Payment Basis: Redemption at par

12. Issuer's/Holders' redemption option: Redemption at the Option of the Issuer

13. Authorised Issue Dates: Issuer Board of Directors Resolution dated 27

April 2023

14. Placement method: Non-syndicated

15. Hybrid Notes Not Applicable

16. Belgian Issue Annex Not Applicable

# TERMS RELATING TO INTEREST (IF ANY) PAYABLE

17. Fixed Rate Notes Not Applicable

18. Floating Rate Notes and Rate Linked Notes Not Applicable

19. **Change of Interest Basis:** Not Applicable

20. Zero Coupon Notes Applicable

(i) Accrual Yield: 4.72 per cent. *per annum* 

(ii) Reference Price: 100% of the Calculation Amount

21. Underlying Reference Linked Interest Notes Not A

other than Rate Linked Notes

Not Applicable

# TERMS RELATING TO REDEMPTION

22. Redemption at the Option of the Issuer Applicable

(i) Optional Redemption Date(s): see table below

(ii) Optional Redemption Amount(s) on each Note and, if relevant, method for calculation of such amount(s):

Optional Redemption Date	Optional Redemption Amount
28 july 2026	114.16% per Calculation Amount
28 july 2027	118.88% per Calculation Amount
28 july 2028	123.60% per Calculation Amount
27 july 2029	128.32% per Calculation Amount
26 july 2030	133.04% per Calculation Amount
28 july 2031	137.76% per Calculation Amount
28 july 2032	142.48% per Calculation Amount

(iii) Optional Redemption in part: Not Applicable

(iv) Notice Period: 15 calendars days prior to the Optional Redemption

Date

23. Redemption at the Option of the Holders Not Applicable 24. Final Redemption Amount on each Note 147.20% per Calculation Amount 25. Underlying Reference Linked Redemption Not Applicable Amount Notes 26. Redemption Amount Switch Option Not Applicable 27. Not Applicable Automatic Early Redemption Event GENERAL PROVISIONS APPLICABLE TO THE NOTES 28. Form of the Notes: Dematerialised Bearer Notes 29. Business Centre or other special provisions Not Applicable relating to Payment Dates: 30. Payment Business Day or other special Following Business Day Convention provisions relating to Payment Business Days: 31. Representation of Holders: Issue outside France: Not Applicable Name and address of the Representative: **UPTEVIA (439 430 976 RCS NANTERRE)** 89-91, rue Gabriel Péri - 92120 Montrouge Represented by Lionel BARTHELEMY Title: Directeur Général Name and address of the alternate Representative: CACEIS BANK (692 024 722 RCS PARIS) 89-91, rue Gabriel Péri - 92120 Montrouge Represented by Carine ECHELARD Title: Managing Director The Representative will receive a remuneration of 500 EUR per year 32. Name and address of the Dealer: Amundi Finance (421 304 601 RCS PARIS) Adresse: 91 – 93 boulevard Pasteur, 75015 Paris Notes may not be offered by Dealers and SPIRICA 33. Non-Exempt Offer: (collectively referred to, with the Dealer, as the Authorised Offerors) other than pursuant to article 1(4) of the Prospectus Regulation in France (Non-Exempt Offer Jurisdictions) during the period from 3 july 2023 (included) to 25 july 2023 (included) (Offer Period). See also paragraph 5 of Part B below.

34.	General Consent:	Not Applicable
35.	Total commission and concession:	Maximum 1.50 per cent per year of the Aggregate Nominal Amount
36.	United States Tax Considerations	The Securities are not Specified Securities for purposes of Section 871(m) of the U.S. Internal Revenue Code of 1986.
37.	Prohibition of Sales to EEA Retail Investors:	Not Applicable
38.	Prohibition of Sales to UK Retail Investors	Applicable
39.	Prohibition of Offer to Private Clients in Switzerland:	Applicable
RESPO	NSIBILITY	
The Issue	er hereby accepts responsibility for the informa	tion contained in these Final Terms.
Signed o	n behalf of the Issuer:	
Ву:		
Duly aut	horised	

### PART B- OTHER INFORMATION

### 1. ADMISSION TO TRADING

(i) Admission to Trading Euronext Paris

Application shall be made by the Issuer (or on its behalf) for the Notes to be admitted to trading on Euronext Paris with effect as from 1 august 2023.

### 2. INTERESTS OF NATURAL AND LEGAL PERSONS INVOLVED IN THE OFFER

The Issuer, the Calculation Agent, the Arranger, the Dealer and the Authorised Offerors are all part of the same group. Potential conflicts of interest may arise.

Save for any fees to the Authorised Offerors, no person involved in the offer of the Notes has, as far as the Issuer is aware, any material interest in the offer. The Dealer, the Authorised Offerors and their affiliates have concluded, and may in the future conclude, financial and commercial transactions with, and may provide other services to, the Issuer during the normal course of business.

## 3. REASONS FOR THE OFFER, ESTIMATED NET PROCEEDS AND TOTAL EXPENSES

(i) Reasons for the offer: The net proceeds will be used for the Issuer's general

corporate purposes

(ii) Estimated net proceeds: Aggregate Nominal Amount of the Tranche

(iii) Estimated Total Expenses: Maximum 1.5 per cent. per annum of the Aggregate

Nominal Amount

## 4. **OPERATIONAL INFORMATION**

ISIN Code: FR001400I962

CFI Code: DSMMMM

Common Code: 263077741

Any clearing system(s) other than Euroclear France/Euroclear Bank SA/NV and

Clearstream Banking S.A. and relevant

identification number(s):

Not Applicable

Delivery: Delivery against payment

Names and addresses of initial Paying

Agent(s):

**UPTEVIA** 

89-91, rue Gabriel Péri

92120 Montrouge

#### France

Names and addresses of additional Paying Not Applicable Agent(s) (if any):

### 5. TERMS AND CONDITIONS OF THE OFFER

Total amount of the securities offered to the 30 000 000 € public/admitted to trading:

Offer Period From 3 july 2023 (included) to 25 july 2023 (the

"Offer End Date") (included)

The Issuer reserves the right to shorten or withdraw the Offer of the Notes, at any time on or prior to the

Offer End Date.

Offer Price: Notes issued will be entirely subscribed by the Dealer

Notes will then be offered to the public on the secondary market during the Offer Period at an Offer

Price equal to 100 € per Notes

Conditions to which the offer is subject: The Issuer reserves the right to withdraw the offer of

the Notes at any time on or prior to the Offer End Date (as defined above). For the avoidance of doubt, if any application has been made by a potential investor and the Issuer exercises such a right, each such potential investor shall not be entitled to subscribe or otherwise acquire the Notes and any application will be automatically cancelled and any purchase monies will be refunded to SPIRICA. In this case, a notice to the investors will be published on the website of the

Issuer (www.amundi.com.)

Description of application procedure (including the period during which the offer shall be open and possible changes):

Applications for the Notes by the public, within the limit of the number of available Notes, will be received in France by Spirica and included in unit-linked life insurance contracts in accordance with the

Authorised Offerors' usual procedures

Description of option to reduce subscriptions and arrangements for refunding of amounts paid in excess paid by subscribers: Not Applicable

Details of the minimum and/or maximum subscription amounts (expressed either as a number of securities or total investment amount): Not Applicable

Details of method and time limits for payment and delivery of Notes:

The Notes will be issued on the Issue Date against payment to the Issuer by the Dealer of the Aggregate Nominal Amount. Investors will be notified by the relevant Authorised Offeror of their allotments of Notes and the settlement arrangements in respect thereof

Manner and date of publication of the results of the offer:

Not Applicable

Procedure for exercise of any pre-emption rights, negotiability of subscription rights and treatment of unexercised subscription rights: Not Applicable

If the Notes are being offered simultaneously in several countries, and if a tranche has been or is being reserved for certain prospective investors, specify which tranche: Not Applicable

Procedure for notifying subscribers of their allotments and indication whether dealing may commence prior to notification:

Not Applicable

Amount of all expenses and taxes charged to the subscriber or purchaser: Not Applicable

Authorised Institution(s) in countries where the Notes are being offered:

Any Authorised Offeror which satisfies the conditions listed below "Conditions relating to Issuer's consent to use the Base Prospectus"

Conditions relating to Issuer's consent to use the Base Prospectus: The conditions to the Issuer's consent are that such consent (a) is only valid during the Offer Period and (b) only extends to the use of the Base Prospectus to make Non-Exempt Offers of the relevant Tranche of Securities in France

# 6. PLACEMENT AND UNDERWRITING

Name(s) and address(es) of entities with overall responsibility for coordinating the issue and the various parties and, to the extent such information is known to the Issuer or the distributor, the relevant dealers in the countries where the Notes are being offered:

The Dealer has appointed the following Authorised Offeror for the distribution of the Notes in France:

Spirica

16-18 Boulevard Vaugirard

**75015 PARIS** 

France

Further information may be obtained by writing to : Spirica 16-18 Boulevard Vaugirard 75015 PARIS.

Name and address of intermediaries acting as paying agents and depositary agents in each relevant country:

Not Applicable

Entities that have agreed to underwrite the Notes on a firm commitment basis and those that have agreed to place the Notes without a firm commitment or under "best efforts" arrangements. If the entire issue has not been underwritten, specify the proportion not underwritten.

Amundi Finance

Overall amount of underwriting commission and of the placing commission:

Maximum 1.5 per cent. per annum of the Aggregate Nominal Amount

Name(s) and address(es) of entities that have undertaken to act as authorised intermediaries on the secondary market, by providing bid/ask price liquidity and description of the main terms of their undertaking:

Amundi Finance has undertaken to act as authorised intermediary on the secondary market, by providing bid price liquidity to the Authorised Offeror under normal market conditions

When the underwriting agreement has been or will be reached:

Issue Date